Assay
LIQUID BIOPSY SSAT1 ASSAY
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique companies using safe therapeutic agents for diagnostic indication. As a non-invasive cost effective red alert tool, it is valuable to physicians around the world. It is a valuable tool for early stage cancer detection.
BioMark has completed comprehensive sets of trials. We are now assembling submission packages for Health Canada. Upon approval, physicians can use BioMark for Lung and Breast cancer screening tests. The results will help assess the need for more definitive imaging or other molecular testing.
Compelling scientific evidence suggests the liquid biopsy SSAT1 assay can expand to include:
- Glioblastoma (GBM) Cancers
- Gastrointestinal Cancers
- Prostate and Head Cancers
- Neck Cancers
